Pharma News

24 June 2025

Blockbuster Heart Drug Ticagrelor Faces Scrutiny Over Trial Integrity and Data Discrepancies

As AstraZeneca’s multibillion-dollar heart drug ticagrelor (marketed as Brilinta in the U.S. and Brilique in Europe) prepares to go off-patent, a fresh investigation by The BMJ has raised troubling concerns about the integrity of the trials that supported its approval. The antiplatelet medication has been widely used for over a decade to treat patients with acute coronary syndrome, but the evidence base it rests on is now under question.

23 June 2025

Emcure Pharmaceuticals to Fully Acquire Zuventus Healthcare

Emcure Pharmaceuticals has announced that its Board of Directors has approved a proposal to acquire the remaining 20.42% minority stake in its subsidiary, Zuventus Healthcare Ltd. The acquisition will result in Zuventus becoming a wholly owned subsidiary of Emcure.

23 June 2025

Lilly's once-weekly insulin efsitora alfa demonstrated A1C reduction and a safety profile consistent with daily insulin in multiple Phase 3 trials

Eli Lilly and Company announced detailed results from QWINT-1, QWINT-3, and QWINT-4 Phase 3 clinical trials evaluating the safety and efficacy of investigational once-weekly insulin efsitora alfa (efsitora) in adults with type 2 diabetes

20 June 2025

Hold the Cream and Sugar : Black Coffee Linked to Lower Risk of Death

The study, published online in The Journal of Nutrition, found that consumption of 1-2 cups of caffeinated coffee per day was linked to a lower risk of death from all causes and death from cardiovascular disease.

20 June 2025

Dupixent® (dupilumab) approved in the U.S

Regeneron Pharmaceuticals, Inc. and Sanofi announced that the U.S. Food and Drug Administration FDA has approved Dupixent dupilumab for the treatment of adult patients with bullous pemphigoid.

20 June 2025

CHMP recommends third indication for darolutamide for patients with advanced prostate cancer

Orion’s collaboration partner Bayer announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended darolutamide, an oral androgen receptor inhibitor , plus androgen deprivation therapy for marketing authorisation in the European Union for the treatment of patients with metastatic hormone-sensitive prostate cancer

20 June 2025

Severe Polyneuritis Successfully Treated with CAR T-Cell Therapy

A team of physicians from Bochum are the first to successfully use CAR T-cell therapy to treat two patients with a rare autoimmune disease of the peripheral nervous system. This treatment modifies endogenous immune cells such that they can specifically target and eliminate B lymphocytes, which are here the origin of autoimmunity.

19 June 2025

Anti-aging drug Rapamycin extends lifespan as effectively as eating less

The anti-aging drug Rapamycin has the same life-extending effect as eating less, according to new research from the University of East Anglia and University of Glasgow

19 June 2025

FDA approves first twice-yearly HIV prevention shot, Yeztugo

In a landmark development, Gilead Sciences announced today that the U.S. Food and Drug Administration has approved Yeztugo (lenacapavir), the first injectable pre-exposure prophylaxis (PrEP) for HIV prevention requiring just two doses per year.

19 June 2025

Fresenius Kabi recalls Blood Administration Sets due to life-threatening risk

Fresenius Kabi has issued an urgent nationwide recall of a specific lot of its Ivenix Large-Volume Pump (LVP) Blood Products Administration Sets, following the discovery of a manufacturing defect that could lead to serious or even fatal consequences.

Search

Blockbuster Heart Drug Ticagrelor Faces Scrutiny Over Trial Integrity and Data Discrepancies

RECOMMENDED POSTS

Subscribe with us

Jobs by Category